The generic landscape has been evolving quickly over the past year and a half and Hoffmann-LaRoche Limited (Roche) needed some in depth expertise to explain where government policies were trending and what it meant for their specialty brands that were soon coming off patent.
Articles about Canadian Critical Paths
September 2011’s Market Insight in Canadian Pharmaceutical Marketing finds Marc Lafoley exploring Subsequent Entry Biologics (SEBs) effect on regulatory approval, pricing and market dynamics.